Characterization of Austrian severe asthma patients

• Published in: Respiratory medicine 2023-11, Vol.219, p.107427-107427, Article 107427
• Main Authors: Renner, Andreas, Stoshikj, Slagjana, Pohl, Wolfgang, Bal, Christina, Reisinger, Matthias, Löffler-Ragg, Judith, Zacharasiewicz, Angela, Buhl, Roland, Hamelmann, Eckard, Taube, Christian, Korn, Stephanie, Idzko, Marco
• Format: Article
• Language: English
• Subjects: Adrenal Cortex Hormones - therapeutic use; Anti-Asthmatic Agents - therapeutic use; Antibodies, Monoclonal - therapeutic use; Asthma; Asthma - drug therapy; Asthma - epidemiology; Asthma control; Austria - epidemiology; Biologics; Humans; Middle Aged; Registry data; Severe asthma; Type-2-inflammation
• ISSN: 0954-6111; 1532-3064
• DOI: 10.1016/j.rmed.2023.107427

The Severe Asthma Registry, founded by German Asthma Net (GAN) in 2011, is a prospective registry recording clinical parameters from participating centers in Germany, Austria and Switzerland. This article presents the baseline characteristics of severe asthma patients from Austrian centers. We analyzed the baseline visit data of all patients recruited to the GAN Severe Asthma Registry from participating Austrian centers. Baseline visit data were available for 214 Austrian severe asthma patients from 6 Austrian centers from 2013 to 2022. Mean age was 53.7 years. Mean BMI was 26.4 kg/m2. More than a third (37.4%) of all patients had daily daytime asthma symptoms at baseline and had to use their reliever medication at least once per day. Forty-one percent of patients were classified as uncontrolled according to GINA and 24.8% as partially controlled at baseline visit. The median annual exacerbation frequency was 3 in the previous 12 months. At the time of baseline visit, 23.4% of all patients had regular treatment with oral corticosteroids. Furthermore, 23.9% had received any severe asthma monoclonal antibody prior to the baseline visit. There were no notable differences in baseline characteristics between patients categorized by smoking history or measurable type 2 inflammation. This study provides the first multi-center characterization of Austrian severe asthma patients. Patients in this cohort had better asthma control and less frequent exacerbations compared to most international registries. •This is the first multi-center characterization of Austrian severe asthma patients.•Patients in this cohort had better asthma control compared to other registries.•Bronchodilator responsiveness was positive in only 30% of tested patients.•Measurable type 2 inflammation had no relevant effect on baseline characteristics.